Non-allergic nature of docetaxel-induced acute hypersensitivity reactions

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 581-585

  Ardavanis, A ^a,b   Tryfonopoulos, D ^a   Yiotis, I ^a   Gerasimidis, G ^a   Baziotis, N ^a   Rigatos, G ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Acute hypersensitivity reactions; Allergy; Docetaxel

Indexed keywords

DOCETAXEL; HISTAMINE; METHYLPREDNISOLONE; PACLITAXEL; TRYPTASE;

ADULT; ARTERIAL PRESSURE; ARTICLE; BACKACHE; BASOPHILIA; BLOOD SAMPLING; BREAST CARCINOMA; BRONCHOSPASM; CANCER PATIENT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME BLOOD LEVEL; EOSINOPHILIA; EPIGASTRIC PAIN; FEMALE; FLUSHING; HEART RATE; HISTAMINE BLOOD LEVEL; HISTAMINE RELEASE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CARCINOMA; PREMEDICATION; PRIORITY JOURNAL; SARCOMA; STOMACH CARCINOMA; THORAX PAIN; TONGUE CARCINOMA;

ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DEOXYCYTIDINE; DOXORUBICIN; DRUG HYPERSENSITIVITY; FEMALE; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PACLITAXEL; PREMEDICATION; SERINE ENDOPEPTIDASES; TACHYCARDIA; TAXOIDS; TIME FACTORS; TRYPTASES;

EID: 3142671875     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000131685.06390.b7     Document Type: Article

References (12)

1. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, et al. Phase I clinical trial of taxotere administrated as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993; 11:950-958.
2. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994; 344: 1267-1272.
3. Cortes J, Pazdur R. Docetaxel. J Clin Oncol 1995; 13:2643-2655.
4. Wanders J, Schrijvers D, Bruntsch U, Gore M, Verweij J, Hanauske A, et al. The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere studies. Proc Am Soc Clin Oncol 1993; 12:73 (abstr 94).
5. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, et al. Coping with the toxicities of docetaxel. Ann Oncol 1993; 4:610-611.
6. Gruchalla R. Understanding drug allergies. J Allergy Clin Immunol 2000; 105:3637-3644.
7. Laroche D, Vergnaud M, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Anesthesiology 1991; 75:945-949.
8. Lin R, Schwartz L, Curry A, Pesola G, Knight R, Lee H, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000; 106:65-71.
9. Nannan Panday VR, Huizing MT, Ten Bokked Huinink WW, Vermorken JB, Beijnen JH. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 1997; 14:418-427.
10. Bissett D, Setanoians A, Cassidy J, Graham M, Chadwick G, Wilson P, et al. Phase I and pharmacokinetic study of taxotere administered as a 24-hour infusion. Cancer Res 1993; 53:523-527.
11. Gruchalla R. Understanding drug allergies. J Allergy Clin Immunol 2000; 105:3637-3644.
12. Lam F, Chan J, Kuhn J. Pharmacokinetics and pharmacodynamics of the taxanes. J Oncol Pharm Practice 1997; 3:76-93.